Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML

[1]  R. Mesa,et al.  Combined venetoclax and alvocidib in acute myeloid leukemia , 2017, Oncotarget.

[2]  Yi Chen,et al.  Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells , 2016, Acta Pharmacologica Sinica.

[3]  A. Strasser,et al.  Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis. , 2016, Cell reports.

[4]  W. Pierceall,et al.  Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs , 2015, PloS one.

[5]  A. Strasser,et al.  Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress. , 2015, Blood.

[6]  S. Leem,et al.  Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. , 2015, Cancer research.

[7]  Scott A. Erickson,et al.  Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. , 2015, Journal of medicinal chemistry.

[8]  S. Mazumder,et al.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies , 2015, Cell Death and Disease.

[9]  A. Letai,et al.  A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) , 2014 .

[10]  V. Gandhi,et al.  Regulation of Mcl-1 Expression in Context to Bone Marrow Stromal Microenvironment in Chronic Lymphocytic Leukemia1 , 2014, Neoplasia.

[11]  J. Krawczyk,et al.  The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells , 2014, Leukemia research reports.

[12]  Ho-June Lee,et al.  Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.

[13]  C. Lutz,et al.  Targeting CDK9 by wogonin and related natural flavones potentiates the anti‐cancer efficacy of the Bcl‐2 family inhibitor ABT‐263 , 2014, International journal of cancer.

[14]  S. Amin,et al.  Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression , 2014, Cancer biology & therapy.

[15]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[16]  James M. Bogenberger,et al.  BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies , 2014, Leukemia.

[17]  H. Dombret,et al.  Outcome of older patients with acute myeloid leukemia in first relapse , 2013, American journal of hematology.

[18]  Afshin Samali,et al.  Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways , 2013, Cell Death and Disease.

[19]  Wei Li,et al.  Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages , 2012, Cell Death and Differentiation.

[20]  M. Borowitz,et al.  A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. , 2012, Blood.

[21]  M. Schuler,et al.  Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies , 2012, Blood Cancer Journal.

[22]  Erinna F. Lee,et al.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. , 2012, Genes & development.

[23]  J. Maciejewski,et al.  An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. , 2011, Blood.

[24]  P. Fisher,et al.  Targeting Mcl-1 for the therapy of cancer , 2011, Expert opinion on investigational drugs.

[25]  Matthew E. Ritchie,et al.  Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 , 2011, Proceedings of the National Academy of Sciences.

[26]  A. Montagnoli,et al.  Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells , 2011, Molecular Cancer Therapeutics.

[27]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Yves Levy,et al.  HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. , 2010, Molecular cell.

[29]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[30]  A. Shilatifard,et al.  AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. , 2010, Molecular cell.

[31]  A. Isacchi,et al.  A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. , 2008, Nature chemical biology.

[32]  M. Warr,et al.  Unique biology of Mcl-1: therapeutic opportunities in cancer. , 2008, Current molecular medicine.

[33]  Soheil Meshinchi,et al.  Identification of genes with abnormal expression changes in acute myeloid leukemia , 2008, Genes, chromosomes & cancer.

[34]  A. Chinnaiyan,et al.  A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. , 2007, Blood.

[35]  J. Opferman.  Life and death during hematopoietic differentiation. , 2007, Current opinion in immunology.

[36]  W. Hiddemann,et al.  BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts , 2007, Leukemia.

[37]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[38]  E. Estey,et al.  Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias , 2006, Molecular Cancer Therapeutics.

[39]  S. Sallan,et al.  Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. , 2006, Experimental hematology.

[40]  P. Kopsombut,et al.  Bcl-x(L) prevents apoptosis of late-stage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin. , 2005, Blood.

[41]  S. Korsmeyer,et al.  Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells , 2005, Science.

[42]  M. Lübbert,et al.  DNA Methylation as a Therapeutic Target in Hematologic Disorders: Recent Results in Older Patients with Myelodysplasia and Acute Myeloid Leukemia , 2004, International journal of hematology.

[43]  B. Löwenberg,et al.  Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. , 2004, Blood.

[44]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Raffeld,et al.  The proapoptotic factor Nix is coexpressed with Bcl-xL during terminal erythroid differentiation. , 2003, Blood.

[46]  S. Edwards,et al.  BCL‐2 family expression in human neutrophils during delayed and accelerated apoptosis , 2001, Journal of leukocyte biology.

[47]  B. Peterlin,et al.  NF-κB Binds P-TEFb to Stimulate Transcriptional Elongation by RNA Polymerase II , 2001 .

[48]  F. Appelbaum,et al.  Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). , 2001, Experimental hematology.

[49]  D. Fennell,et al.  In vivo suppression of Bcl‐XL expression facilitates chemotherapy‐induced leukaemia cell death in a SCID/NOD‐Hu model , 2001, British journal of haematology.

[50]  S. Edwards,et al.  In vivo localisation and stability of human Mcl‐1 using green fluorescent protein (GFP) fusion proteins , 2000, FEBS letters.

[51]  D. Price.  P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II , 2000, Molecular and Cellular Biology.

[52]  M. Byrne,et al.  Dissecting the Marrow Microenvironment , 1999, Annals of the New York Academy of Sciences.

[53]  John Calvin Reed,et al.  Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. , 1998, Blood.

[54]  J. Rouault,et al.  Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells , 1994 .

[55]  C. Bloomfield,et al.  Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. , 1981, Blood.

[56]  J. Holland,et al.  Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. A study by cancer and leukemia group B , 1979, Cancer.

[57]  R. Burgkart,et al.  Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients , 2016, Leukemia.

[58]  C. Müller-Tidow,et al.  DNA methylation as a pathogenic event and as a therapeutic target in AML. , 2011, Cancer treatment reviews.

[59]  M. Konopleva,et al.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins , 2002, Leukemia.

[60]  B. Peterlin,et al.  NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. , 2001, Molecular cell.

[61]  J. Rouault,et al.  Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. , 1994, Blood.